2021, Number 2
<< Back Next >>
Rev Hematol Mex 2021; 22 (2)
Relationship between the amount of hematopoietic cells infused and hematological recovery in autologous transplantation
Varela-Constantino AL, De la Rosa-Flores GA, De la Garza-Salazar F, Contreras-Arce A, Gómez-De León A, Colunga-Pedraza P, Cantú-Rodríguez O, Jaime-Pérez JC, Gómez-Almaguer D, Gutiérrez-Aguirre CH
Language: Spanish
References: 13
Page: 80-87
PDF size: 219.14 Kb.
ABSTRACT
Objective: To determine if there is a difference in time of hematological recovery
in a group of patients with multiple myeloma, Hodgkin lymphoma or non-Hodgkin
lymphoma who received an autologous hematopoietic cell transplant (auto-HCT), according
to the number of hematopoietic cells infused.
Materials and Methods: A retrospective, descriptive and observational study, carried
out in the Hematology Service of the Dr. Jose Eleuterio Gonzalez University Hospital
of the Autonomous University of Nuevo Leon, Mexico, by analyzing the clinical records
of patients who received an auto-HCT in the period from January 2018 to December
2020. Patients older than 18 years with a diagnosis of Hodgkin lymphoma, non-Hodgkin
lymphoma, multiple myeloma or other plasma cell neoplasms were included.
Results: 72 patients were included, 36 female, with a median age of 56 years. The
median time for neutrophil recovery was 12 days in the three groups of patients, without
significant difference (p = 0.78), while for platelet recovery it was longer in the
group of patients that received ‹ 2 x 106/kg CD34+ cells (15 vs 12 days), but without
significant difference (p = 0.15).
Conclusions: Despite there are not significant differences in post-transplant hematological
recovery time, there is an association between the greater amount of CD34+
cells infused and a lower risk of febrile neutropenia and the need for hospitalization
in patients who receive an autologous hematopoietic cell transplant obtained from
peripherally blood.
REFERENCES
Philip T, Guglielmi C, Hagenbeek A, Somers R, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapysensitive non-hodgkin’s lymphoma. N Engl J Med 1995; 333 (23): 1540-1545. doi. 10.1056/nejm199512073332305.
Björkstrand B, Goldstone AH, Ljungman P, Brandt L, et al. Prognostic factors in autologous stem cell transplantation for multiple myeloma: An EBMT registry study. Leuk Lymphoma 1994; 15 (3-4): 265-272. doi. 10.3109/10428199409049723.
Pecora AL. Impact of stem cell dose on hematopoietic recovery in autologous blood stem cell recipients. Bone Marrow Transplant 1999; 23: S7-S12. doi. 10.1038/sj.bmt.1701668.
Sutherland DR, Stewart AK, Keating A. CD34 Antigen: Molecular features and potential clinical applications. Stem Cells 1993; 11 Suppl 3: 50-7. doi. 10.1002/stem.5530110914.
Siena S, Bregni M, Brando B, Belli N, et al. Flow cytometry for clinical estimation of circulating hematopoietic progenitors for autologous transplantation in cancer patients. Blood 1991; 77 (2): 400-409. doi. 10.1182/blood. v77.2.400.400.
Chao NJ, Schriber JR, Grimes K, Long GD, et al. Granulocyte colony-stimulating factor “mobilized” peripheral blood progenitor cells accelerate granulocyte and platelet recovery after high-dose chemotherapy. Blood 1993; 81 (8): 2031-2035. doi. 10.1182/blood.v81.8.2031.bloodjournal8182031.
Siena S, Schiavo R, Pedrazzoli P, Carlo-Stella C. Therapeutic relevance of CD34+ cell dose in blood cell transplantation for cancer therapy. J Clin Oncol 2000; 18 (6): 1360-1377. doi. 10.1200/JCO.2000.18.6.1360.
Haas R, Mohle R, Fruhauf S, Goldschmidt H, et al. Patient characteristics associated with successful mobilizing and autografting of peripheral blood progenitor cells in malignant lymphoma. Blood 1994; 83 (12): 3787-3794. doi. 10.1182/blood.v83.12.3787.3787.
Ketterer N, Salles G, Raba M, Espinouse D, et al. High CD34+ cell counts decrease hematologic toxicity of autologous peripheral blood progenitor cell transplantation. Blood 1998; 91 (9): 3148-3155. doi. 10.1182/blood.v91.9.3148.
Carreras E, Dufour C, Mohty M, Kröger N, editors. The EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies [Internet]. 7th ed. Cham (CH): Springer; 2019.
Hopman R, DiPersio J. Advances in Stem Cell Mobilization. Blood Rev. 2014; 28 (1): 31-40.
Hosing C, Saliba RM, Ahlawat S, Korbling M, et al. Poor hematopoietic stem cell mobilizers: a single institution study of incidence and risk factors in patients with recurrent or relapsed lymphoma. Am J Hematol 2009; 84: 335-7. doi: 10.1002/ajh.21400.
Gutiérrez-Aguirre C, De la Garza-Salazar F, Cantú-Rodríguez O, González-Llano O, et al. Comparación de la efectividad de la movilización de células hematopoyéticas con quimioterapia y filgrastim, o con filgrastim solo, para autotrasplante en pacientes con linfoma. Gac Med Mex 2016; 152: 57-65.
Full text